GPX4 and metabolic dysfunction-associated steatohepatitis: Similarly, In another NASH mouse modeling by MCD feeding, liver steatosis aggravated after RSL3 (ferroptosis inducer) administration, whereas the severity of NASH was significantly alleviated after treatment with sodium selenite (GPX4 activator), deferoxamine (iron-chelating agent) and ferrostatin-1 (ferroptosis inhibitor) (Qi et al. 2020).